Back In Fashion? Boston’s CBO Talks Turkey On Reinvigorating Pharma’s Unwanted Assets

Constantine Chinoporos, Boston Pharmaceuticals’ CBO, talks to Scrip about its deal strategy and how it intends to build its pipeline over the next few years, liberated from the constraints of portfolio management.

Catwalk — Boston develops pharma’s out-of-style assets and aims to match them with interested parties • Source: Shutterstock

“Anti-infectives are ugly stepchildren these days,” Boston Pharmaceuticals Inc.’s fast-talking chief business officer Constantine Chinoporos tells Scrip, when describing how its October asset haul played out. “Our calculus is that someday, with 23,000 people dying in the US of drug-resistant bacteria, this isn’t going to go away.”

The anti-infectives Chinoporos refers to are three assets bought in October as part of a licensing and equity agreement with Novartis AG

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Quick Listen: Scrip’s Five Must-Know Things

12 May 2025

• By Ian Haydock

In this week's episode: industry makes its case to Trump; Sarepta slammed by double blow; Chinese firms build obesity pipeline; Swiss biopharma staying strong; and Merck & Co looks to immunology and ophthalmology.